Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5808669 | 1.00 | HDAC6 (0.39) | HDAC6HDAC1NLRP3ATMTACR1 | |
| SCHEMBL5810645 | 0.89 | TACR1 (0.39) | NLRP3TACR1THRB | |
| SCHEMBL5810644 | 0.89 | TACR1 (0.39) | NLRP3TACR1THRB | |
| SCHEMBL5813144 | 0.88 | KDM4E (0.36) | NLRP3TACR1ALDH1A1 | |
| SCHEMBL5813150 | 0.88 | KDM4E (0.36) | NLRP3TACR1ALDH1A1 | |
| SCHEMBL29103272 | 0.87 | HDAC6 (0.36) | HDAC6HDAC1NLRP3ATMALDH1A1 | |
| SCHEMBL5814148 | 0.87 | TACR1 (0.35) | TACR1ALDH1A1CYP2C9CYP2C19POLB | |
| SCHEMBL30325287 | 0.87 | TGFBR1 (0.37) | HDAC6HDAC1NLRP3ATMALDH1A1 | |
| SCHEMBL28712459 | 0.87 | TGFBR1 (0.37) | HDAC6HDAC1NLRP3ATMALDH1A1 | |
| SCHEMBL5814144 | 0.87 | TACR1 (0.35) | TACR1ALDH1A1CYP2C9CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | claimed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | claimed |
| CN-113816908-A | Method for realizing alkylation of histidine or polypeptide thereof by using micro-channel photoreaction technology | 南京先进生物材料与过程装备研究院有限公司 | 2021-12-21 | — | — | CN | disclosed |
| US-20070149441-A1 | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same | ORTHOGENE LLC (US) | 2007-06-28 | — | — | US | disclosed |
| US-7196180-B2 | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same | ORTHOGENE LLC (US) | 2007-03-27 | — | — | US | disclosed |
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149441-A1 | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same | CD44, HDGF, HAAO | HDAC6 297/4885HDAC1 719/4885NLRP3 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.